All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for MERCK & CO., INC. · developer, manufacturer and distributor of pharmaceuticals

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $40,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 2

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 891
Bipartisan Health Care Act

Lobbying activity 6

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs.

Budget/Appropriations

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Health Issues

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), antimicrobial resistance, VICP Program, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.